Literature DB >> 2211198

Prophylactic irradiation of the para-aortic lymph node chain in stage IIB and bulky stage IB carcinoma of the cervix, initial treatment results of RTOG 7920.

M Rotman1, K Choi, C Guse, V Marcial, N Hornback, M John, C Guze.   

Abstract

From November 1979 to October 1986, 367 patients were entered onto RTOG 7920 and randomized to receive either pelvic irradiation alone or pelvic plus para-aortic radiation. Patients with Stage IIB cervical carcinoma who had not undergone curative surgery and patients with Stages IB and IIA cervical carcinoma who were determined by digital exam to have primary tumors measuring 4 cm or greater in lateral dimension were eligible for this study. Clinically apparent or surgically involved para-aortic nodes were reason for exclusion from the study. Pelvic irradiation consisted of 1.6-1.8 Gy per day for 5 days per week to a total of 40-50 Gy. Para-aortic irradiation delivered 44 to 45 Gy in 1.6-1.8 Gy per day, 5 days per week. Pelvic irradiation was to be completed in 4 1/2 to 6 1/2 weeks and para-aortic irradiation in 4 1/2 to 5 1/2 weeks. Intracavitary brachytherapy delivered a total of 4000-5000 mg hr of radium-equivalents or 30-40 Gy to point A. Patients were stratified prior to random treatment assignment by histology, para-aortic nodal status (negative vs. unevaluated), and FIGO stage. As of June 1, 1989, 30 cases were excluded, including five patients who were inevaluable. Two patients who refused the assigned treatment were also excluded. Therefore, a total of 330 cases were analyzable. At 5 years the estimates of survival, the primary endpoint, for the pelvic only and pelvic plus para-aortic irradiation arms are 55% and 65%, respectively (p = 0.043). Several secondary endpoints were also analyzed. Estimates for loco-regional control at 5 years are, for pelvic irradiation only, 66%, and for pelvic plus para-aortic irradiation, 75% (p = 0.21). Distant metastases are estimated in 32% of pelvic irradiation only patients and 25% of pelvic plus para-aortic irradiation patients at 5 years (p = 0.17). When the first disease failure patterns are examined, more patients fail distally when treated only with pelvic radiation than when using pelvic plus para-aortic fields (p = .04). In analysis of patients with grade 3 (severe), grade 4 (life-threatening), and grade 5 (fatal complications), 8% of the patients in both groups had grade 3 severe complications. In the pelvic plus para-aortic group, 11 patients had grade 4 and 2 had grade 5 complications, whereas 6 had grade 4 and none had grade 5 in the pelvic only treatment group.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2211198     DOI: 10.1016/0360-3016(90)90475-y

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  [Standard versus individually planned irradiation field in radiotherapy of infradiaphragmatic lymph node sites].

Authors:  M Nevinny-Stickel; S Ennemoser; I Bangerl; D zur Nedden; P Lukas
Journal:  Strahlenther Onkol       Date:  1998-07       Impact factor: 3.621

Review 2.  Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials.

Authors:  Lucas Gomes Sapienza; Maria José Leite Gomes; Vinicius Fernando Calsavara; Mario M Leitao; Glauco Baiocchi
Journal:  Gynecol Oncol       Date:  2016-11-28       Impact factor: 5.482

3.  Adjuvant radiotherapy after radical hysterectomy of the cervical cancer. Prognostic factors and complications.

Authors:  M Chatani; T Nose; N Masaki; T Inoue
Journal:  Strahlenther Onkol       Date:  1998-10       Impact factor: 3.621

4.  Lymph flow guided irradiation of regional lymph nodes in patients with cervical cancer: Preliminary analysis of scintigraphic data.

Authors:  Sergey Nikolaevich Novikov; Pavel Ivanovich Krzhivitskii; Sergey Vasilevich Kanaev; Igor Viktorovitch Berlev; Margarita Viktorovna Kargopolova; Zaur Ibragimov; Mikhail Bisyarin; Valentina Vladimirovna Saveleva
Journal:  Rep Pract Oncol Radiother       Date:  2018-06-12

Review 5.  Radiotherapy for cervical cancer: Chilean consensus of the Society of Radiation Oncology.

Authors:  Felipe Carvajal; Claudia Carvajal; Tomás Merino; Verónica López; Javier Retamales; Evelyn San Martín; Freddy Alarcón; Mónica Cuevas; Francisca Barahona; Ignacio Véliz; Juvenal A Ríos; Sergio Becerra
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

6.  Para-Aortic Nodal Radiation in the Definitive Management of Node-Positive Cervical Cancer.

Authors:  Jason C Sanders; Donald A Muller; Sunil W Dutta; Taylor J Corriher; Kari L Ring; Timothy N Showalter; Kara D Romano
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

7.  Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer.

Authors:  Jeong-Yeol Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Young-Seok Kim; Ha Jeong Kim; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Seung Jae Huh; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

8.  Extended-field radiotherapy for locally advanced cervical cancer.

Authors:  Komsan Thamronganantasakul; Narudom Supakalin; Chumnan Kietpeerakool; Porjai Pattanittum; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26

9.  Is extended-field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer?

Authors:  Mushabbab Al Asiri; Mutahir A Tunio; Reham Mohamed; Yasser Bayoumi; Abdulrehman Alhadab; Rasha M Saleh; Muhannad Saud AlArifi; Abdelaziz Alobaid
Journal:  Cancer Manag Res       Date:  2014-09-09       Impact factor: 3.989

10.  Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer.

Authors:  Jinju Oh; Ki Ho Seol; Hyun Joo Lee; Youn Seok Choi; Ji Y Park; Jin Young Bae
Journal:  Radiat Oncol J       Date:  2017-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.